NURS 6501 Week 3: sample paper, in real form

Systemic Lupus Erythematosus in a 27-Year-Old Woman: Loss of Self-Tolerance, Immune Complex Injury, and Genetic Susceptibility

Student Name

College of Nursing, Walden University

NURS 6501: Advanced Pathophysiology

Instructor Name

Month Day, Year

Case Presentation and the Question It Raises

The patient described here is an illustrative composite assembled for teaching, and no part of this case is taken from a real person or a real record. A.J. is a 27-year-old Black woman seen in primary care for four months of fatigue, diffuse hair thinning, and painless oral ulcers, with symmetric pain and 45 minutes of morning stiffness in the wrists and the small joints of both hands. Two weeks after a weekend at the shore she developed a raised rash across both cheeks and the bridge of the nose that spared the nasolabial folds. She has lost 3.2 kg without trying. Blood pressure is 148/92 and temperature is 99.8 F. Her mother has hypothyroidism and an aunt has rheumatoid arthritis. She takes no medication other than an oral contraceptive and reports no recent infection.

Laboratory studies show a white blood cell count of 3,100 per cubic millimeter with 800 lymphocytes, hemoglobin of 10.4 g/dL, and a platelet count of 118,000 per cubic millimeter. Serum creatinine is 1.3 mg/dL, urinalysis shows 2+ protein with 8 to 10 red cells per high-power field and one red cell cast, and the urine protein-to-creatinine ratio is 1.8 g/g. Antinuclear antibody is positive at 1:1280 in a homogeneous pattern, anti-double-stranded DNA is 210 IU/mL, and anti-Smith antibody is present. C3 is 58 mg/dL and C4 is 9 mg/dL, both below the reference range, while the erythrocyte sedimentation rate is 62 mm/hr and C-reactive protein is 0.6 mg/dL. The question this case raises is not what to call the disease but how one immune failure produces findings in the skin, the joints, the blood, and the kidney at once.

Loss of Self-Tolerance and the Interferon Amplification Loop

Lupus begins as a failure of disposal rather than a failure of defense. Cells die by apoptosis constantly, and their nuclear contents, among them double-stranded DNA, histones, and small nuclear ribonucleoproteins, are normally packaged and cleared within minutes by complement proteins, phagocytes, and nuclease activity (McCance & Huether, 2019). When that clearance is slow or incomplete, nucleosomal debris persists in tissue and in the circulation long enough to be sampled by antigen-presenting cells. Ultraviolet light accelerates the same process from the other end, driving keratinocyte apoptosis and moving nuclear antigens to the cell surface, which is the mechanistic reason this patient's rash appeared after two days at the shore rather than at random (Kaul et al., 2016). The antigen driving the disease is therefore self, abundant, and continuously resupplied.

What converts persistent debris into autoimmunity is the way the innate immune system reads it. Nucleic acid bound to antibody is taken into plasmacytoid dendritic cells and delivered to endosomal Toll-like receptors 7 and 9, which evolved to detect viral RNA and DNA and cannot distinguish the patient's own nucleic acid from a pathogen's (Tsokos et al., 2016). Those receptors trigger large-scale production of type I interferon, and the resulting interferon signature is measurable in most patients with active disease (Crow, 2014). Interferon then acts back on the system that produced it: it matures dendritic cells, lowers the activation threshold of autoreactive B cells, raises survival factors such as B-cell activating factor, and recruits T follicular helper support for class switching. The loop sustains itself, which is why the disease relapses rather than resolving.

The B-cell output of that loop is what the laboratory measures. Autoreactive B cells that would normally be deleted or made anergic instead mature into plasma cells producing high-affinity IgG against double-stranded DNA, Smith antigen, and other nuclear targets. These antibodies bind soluble antigen in the circulation and form immune complexes that deposit where filtration pressure is highest, which is the glomerulus, and that is type III hypersensitivity in its clearest clinical form (McCance & Huether, 2019). Deposited complexes fix complement through the classical pathway, generating C3a and C5a, recruiting neutrophils, and consuming C3 and C4 faster than the liver replaces them. The falling complement level is therefore not incidental; it is a direct footprint of ongoing complex formation, which is why it tracks disease activity (Tsokos, 2011).

Genetic Susceptibility, Sex Bias, and Environmental Triggers

Lupus is polygenic, and the risk alleles cluster in the pathways described above. Class II human leukocyte antigen variants shape which self-peptides are presented; polymorphisms in IRF5 and STAT4 sit inside the interferon pathway; and variants in PTPN22 and in Fc receptor genes alter lymphocyte activation thresholds and complex clearance (Kaul et al., 2016). The most instructive genetics are the complement deficiencies. Homozygous C1q deficiency carries a lupus risk above 90 percent, and C2 and C4 deficiencies raise risk substantially, which looks paradoxical beside the low C3 and C4 in this patient until the two roles are separated: complement is needed to clear apoptotic debris, so lacking it causes disease, while consuming it marks disease that is already active (Tsokos et al., 2016). Heritability is real but partial, since concordance in identical twins is roughly 25 to 40 percent rather than complete.

Sex is the strongest demographic factor, with roughly nine women affected for every man during the reproductive years. Two mechanisms are proposed and are not exclusive: estrogen effects on B-cell survival and antibody production, and gene dosage from the X chromosome, where TLR7 escapes X inactivation in a fraction of immune cells so that some women express it from both copies (Crow, 2014). Environmental contributors include ultraviolet exposure, Epstein-Barr virus infection, silica dust, cigarette smoking, and several drugs, most of which act by raising apoptotic load or by altering DNA methylation in T cells. Prevalence in the United States is estimated near 73 cases per 100,000 people and runs about three times higher in Black women, who also develop nephritis earlier and more often (Centers for Disease Control and Prevention, 2024). Genetic risk and social determinants both contribute to that gap, and neither alone accounts for it.

Mapping the Mechanism onto This Patient

Each abnormal finding in this case now has an address in the mechanism. The malar rash following sun exposure is ultraviolet-driven keratinocyte apoptosis with antibody and complement deposition at the dermal-epidermal junction. The symmetric small-joint pain with morning stiffness is synovial immune complex deposition, which inflames without producing the erosive destruction of rheumatoid disease. The proteinuria, red cells, and single red cell cast place the injury in the glomerulus rather than the lower urinary tract, and the protein-to-creatinine ratio of 1.8 g/g quantifies it. The cytopenias have a different immunologic address: antibodies against surface antigens on red cells and platelets mark them for splenic removal, which is type II hypersensitivity operating in the same patient as type III (McCance & Huether, 2019). Low C3 and C4 with a high anti-double-stranded DNA titer date the activity to now.

Two findings deserve a closer reading, because students often treat them as errors. A sedimentation rate of 62 mm/hr with a C-reactive protein of 0.6 mg/dL is a recognized pattern in active lupus, since the sedimentation rate reflects immunoglobulin and fibrinogen while type I interferon suppresses hepatic C-reactive protein production; a high C-reactive protein in this patient would point toward infection instead (Tsokos, 2011). Mechanism also sets the monitoring. Complement levels and anti-double-stranded DNA titers are followed because they move with complex formation, urine protein is quantified because the kidney is where deposition does the most damage, and renal biopsy is what establishes class. Reading the mechanism is what turns a page of abnormal values into a plan with a reason behind each item.

References

Centers for Disease Control and Prevention. (2024). Systemic lupus erythematosus (SLE). U.S. Department of Health and Human Services. https://www.cdc.gov/lupus/

Crow, M. K. (2014). Type I interferon in the pathogenesis of lupus. The Journal of Immunology, 192(12), 5459-5468.

Kaul, A., Gordon, C., Crow, M. K., Touma, Z., Urowitz, M. B., van Vollenhoven, R., Ruiz-Irastorza, G., & Hughes, G. (2016). Systemic lupus erythematosus. Nature Reviews Disease Primers, 2, Article 16039.

McCance, K. L., & Huether, S. E. (2019). Pathophysiology: The biologic basis for disease in adults and children (8th ed.). Elsevier.

Tsokos, G. C. (2011). Systemic lupus erythematosus. New England Journal of Medicine, 365(22), 2110-2121.

Tsokos, G. C., Lo, M. S., Costa Reis, P., & Sullivan, K. E. (2016). New insights into the immunopathogenesis of systemic lupus erythematosus. Nature Reviews Rheumatology, 12(12), 716-730.